vs
Side-by-side financial comparison of Vita Coco Company, Inc. (COCO) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Vita Coco Company, Inc. is the larger business by last-quarter revenue ($179.8M vs $177.4M, roughly 1.0× Pacira BioSciences, Inc.). Vita Coco Company, Inc. runs the higher net margin — 17.0% vs 1.6%, a 15.3% gap on every dollar of revenue. On growth, Vita Coco Company, Inc. posted the faster year-over-year revenue change (37.3% vs 5.0%). Over the past eight quarters, Vita Coco Company, Inc.'s revenue compounded faster (11.7% CAGR vs -0.2%).
The Vita Coco Company, doing business simply as Vita Coco, is an American beverage company which mainly sells coconut water. The largest brand globally in coconut/plant waters, Vita Coco has operations in 31 countries as of 2016. It is a benefit corporation. The company is owned by All Market Inc.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
COCO vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $179.8M | $177.4M |
| Net Profit | $30.5M | $2.9M |
| Gross Margin | 39.9% | — |
| Operating Margin | 18.7% | 3.9% |
| Net Margin | 17.0% | 1.6% |
| Revenue YoY | 37.3% | 5.0% |
| Net Profit YoY | 61.4% | — |
| EPS (diluted) | $0.50 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $179.8M | $177.4M | ||
| Q4 25 | $127.8M | $196.9M | ||
| Q3 25 | $182.3M | $179.5M | ||
| Q2 25 | $168.8M | $181.1M | ||
| Q1 25 | $130.9M | $168.9M | ||
| Q4 24 | $127.3M | $187.3M | ||
| Q3 24 | $132.9M | $168.6M | ||
| Q2 24 | $144.1M | $178.0M |
| Q1 26 | $30.5M | $2.9M | ||
| Q4 25 | $5.5M | — | ||
| Q3 25 | $24.0M | $5.4M | ||
| Q2 25 | $22.9M | $-4.8M | ||
| Q1 25 | $18.9M | $4.8M | ||
| Q4 24 | $3.4M | — | ||
| Q3 24 | $19.3M | $-143.5M | ||
| Q2 24 | $19.1M | $18.9M |
| Q1 26 | 39.9% | — | ||
| Q4 25 | 34.9% | 79.5% | ||
| Q3 25 | 37.7% | 80.9% | ||
| Q2 25 | 36.3% | 77.4% | ||
| Q1 25 | 36.7% | 79.7% | ||
| Q4 24 | 32.5% | 78.7% | ||
| Q3 24 | 38.8% | 76.9% | ||
| Q2 24 | 40.8% | 75.1% |
| Q1 26 | 18.7% | 3.9% | ||
| Q4 25 | 8.0% | 1.2% | ||
| Q3 25 | 15.3% | 3.5% | ||
| Q2 25 | 14.9% | 4.7% | ||
| Q1 25 | 14.7% | 1.2% | ||
| Q4 24 | 3.4% | 13.2% | ||
| Q3 24 | 15.5% | -82.8% | ||
| Q2 24 | 20.8% | 15.9% |
| Q1 26 | 17.0% | 1.6% | ||
| Q4 25 | 4.3% | — | ||
| Q3 25 | 13.2% | 3.0% | ||
| Q2 25 | 13.6% | -2.7% | ||
| Q1 25 | 14.4% | 2.8% | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 14.5% | -85.1% | ||
| Q2 24 | 13.2% | 10.6% |
| Q1 26 | $0.50 | $0.07 | ||
| Q4 25 | $0.10 | $0.05 | ||
| Q3 25 | $0.40 | $0.12 | ||
| Q2 25 | $0.38 | $-0.11 | ||
| Q1 25 | $0.31 | $0.10 | ||
| Q4 24 | $0.06 | $0.38 | ||
| Q3 24 | $0.32 | $-3.11 | ||
| Q2 24 | $0.32 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $201.9M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $352.2M | $653.9M |
| Total Assets | $488.3M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $201.9M | $144.3M | ||
| Q4 25 | $196.9M | $238.4M | ||
| Q3 25 | $203.7M | $246.3M | ||
| Q2 25 | $167.0M | $445.9M | ||
| Q1 25 | $153.6M | $493.6M | ||
| Q4 24 | $164.7M | $484.6M | ||
| Q3 24 | $156.7M | $453.8M | ||
| Q2 24 | $150.1M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $352.2M | $653.9M | ||
| Q4 25 | $331.5M | $693.1M | ||
| Q3 25 | $323.7M | $727.2M | ||
| Q2 25 | $296.9M | $757.8M | ||
| Q1 25 | $277.9M | $798.5M | ||
| Q4 24 | $258.8M | $778.3M | ||
| Q3 24 | $252.1M | $749.6M | ||
| Q2 24 | $232.0M | $879.3M |
| Q1 26 | $488.3M | $1.2B | ||
| Q4 25 | $461.2M | $1.3B | ||
| Q3 25 | $461.3M | $1.3B | ||
| Q2 25 | $421.1M | $1.5B | ||
| Q1 25 | $384.0M | $1.6B | ||
| Q4 24 | $362.4M | $1.6B | ||
| Q3 24 | $353.1M | $1.5B | ||
| Q2 24 | $323.0M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COCO
| Subtotal | $148.2M | 82% |
| Private Label | $24.4M | 14% |
| Other | $7.2M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
